Seeger Weiss LLP Reports On Benicar Lawsuits Reaching 915

Aug 24, 2015, 12:36 ET from Seeger Weiss LLP

NEW YORK, Aug. 24, 2015 /PRNewswire/ -- Seeger Weiss LLP is reporting that the number of Benicar lawsuits in the multidistrict litigation, as of July 15, 2015, has reached 915 lawsuits—an increase of 70 since the previous month. These lawsuits are against the makers of Benicar, Daiichi Sankyo, Inc., its parent company, Daiichi Sankyo Co. Ltd., and Forest Laboratories Inc., a company alleged to be involved in promoting Benicar. Benicar is a drug used in patients with high blood pressure and has been associated with the development of sprue-like enteropathy, which can cause severe gastrointestinal symptoms such as chronic diarrhea, nausea and vomiting, and significant weight loss and malnutrition.

The drug was approved by the FDA in April 2002, but, in July 2013 the FDA issued a Safety Announcement for Benicar after reviewing data submitted by the Mayo Clinic. The data showed that the drug may be associated with sprue-like enteropathy. The first lawsuits against Daiichi Sankyo were filed soon after the FDA issued the warning. This multidistrict litigation was formed in April 2015 and is based in the US District Court in New Jersey.

Plaintiffs in the multidistrict litigation allege, in part, that Benicar is unreasonably dangerous, negligently designed, and misleadingly marketed. Plaintiffs also allege that studies concerning Benicar's side effects were "submitted on a delayed basis to the FDA."

Seeger Weiss LLP represents a large number of individuals alleging injury as the result of ingesting Benicar and is one of the nation's leading trial law firms handling complex individual, mass and class action litigation on behalf of consumers, investors, injured persons and whistleblowers. The firm, with offices in New York, Philadelphia and New Jersey, represents plaintiffs throughout litigation and as trial counsel in a variety of practice areas, including financial, securities and investment fraud, pharmaceutical injury, consumer protection, qui tam (whistleblower cases), environmental and asbestos exposures, personal injury and medical malpractice, product defect, antitrust, and commercial disputes. For more information, go to www.seegerweiss.com.

For more information on Benicar, or if you believe you have been injured by using Benicar, go to our Benicar Lawsuit page.

http://news.frx.com/press-release/product-news/fda-grants-marketing-approval-benicar-olmesartan-medoxomil-treatment-hype

http://www.fda.gov/downloads/Drugs/DrugSafety/UCM359496.pdf

http://www.ncbi.nlm.nih.gov/pubmed/22728033

http://www.law360.com/articles/640387/jpml-centralizes-15-suits-over-benicar-side-effects-in-nj

http://www.jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-August-17-2015.pdf

Contact: 
Christopher A. Seeger, (212) 584-0700 or cseeger@seegerweiss.com 
Jeffrey S. Grand (212) 584-0700 or jgrand@seegerweiss.com 

Logo - http://photos.prnewswire.com/prnh/20150527/218876LOGO

SOURCE Seeger Weiss LLP



RELATED LINKS

http://www.seegerweiss.com